<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="372">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02033941</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 09-0307</org_study_id>
    <secondary_id>5R21AT005510</secondary_id>
    <nct_id>NCT02033941</nct_id>
  </id_info>
  <brief_title>Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)</brief_title>
  <official_title>Phase II Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hillel Grossman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer Disease (AD) is a progressive brain disease generally known as senile dementia. Our&#xD;
      proposed study will establish safety and pharmacokinetics of Meganatural-AZ GSPE in AD&#xD;
      subjects. As secondary measures, we will also provide the essential human data to guide the&#xD;
      design of future studies to test the efficacy of GSPE in mitigating cognitive deterioration&#xD;
      in AD patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to establish the safety and pharmacokinetics of Meganatural-Az® GSPE in&#xD;
      subjects with Alzheimer's disease. As a secondary goal, clinical and biomarker indices of&#xD;
      therapeutic efficacy will also be evaluated. The proposed study will provide the essential&#xD;
      human data necessary to guide the design of future studies testing the efficacy of GSPE in&#xD;
      mitigating cognitive deterioration in AD patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetic analysis</measure>
    <time_frame>up to 22 months</time_frame>
    <description>the pharmacokinetics and effects of Meganatural-Az® on tau and abnormally phosphorylated tau CSF concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>primary safety evaluations</measure>
    <time_frame>up to 22 months</time_frame>
    <description>adverse effects reporting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AD Biomarkers</measure>
    <time_frame>up to 22 months</time_frame>
    <description>β-amyloid (Aβ) in plasma and in cerebral spinal fluid (CSF) specimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive and functional assessments</measure>
    <time_frame>up to 22 months</time_frame>
    <description>cognitive and functional assessments including the ADAS-cog, ADCS CGIC, MMSE, and ADL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Meganatural-Az Grapeseed Extract</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receive capsules identical in appearance to the active agent with the same incremental schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meganatural-Az Grapeseed Extract</intervention_name>
    <description>Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day</description>
    <arm_group_label>Meganatural-Az Grapeseed Extract</arm_group_label>
    <other_name>Grapeseed Polyphenolic Extract</other_name>
    <other_name>Grapeseed Phenol Extract</other_name>
    <other_name>GSPE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects receive capsules identical in appearance to the active agent with the same incremental schedule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NINCDS/ADRDA criteria for probable AD&#xD;
&#xD;
          -  MMSE between 12-26&#xD;
&#xD;
          -  Treatment with a cholinesterase inhibitor or an NMDA (N-methyl-D-asparate) antagonist&#xD;
             with stable dose for at least 12 weeks&#xD;
&#xD;
          -  Home monitoring available for supervision of medications&#xD;
&#xD;
          -  Caregiver available to accompany patient to all visits and willing to participate in&#xD;
             study as informant&#xD;
&#xD;
          -  Fluent in English or Spanish&#xD;
&#xD;
          -  Medical stability for this study as confirmed by review of records, internist's&#xD;
             physical exam, neurological exam, and laboratory tests&#xD;
&#xD;
          -  Stable doses of non-excluded medication&#xD;
&#xD;
          -  No evidence of hepatic insufficiency&#xD;
&#xD;
          -  Able to swallow oral medications&#xD;
&#xD;
          -  Ability to participate in the informed consent process&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypotension or unstable hypertension&#xD;
&#xD;
          -  Active hepatic or renal disease&#xD;
&#xD;
          -  Use of another investigational drug within the past two months&#xD;
&#xD;
          -  History of clinically significant stroke&#xD;
&#xD;
          -  History of seizure or head trauma with disturbance of consciousness within the past&#xD;
             two years&#xD;
&#xD;
          -  Major mental illness including psychotic disorders, bipolar disorder, or major&#xD;
             depressive episode that is not in remission for less than 12 months&#xD;
&#xD;
          -  Women of child-bearing age unless using effective birth control or at least one year&#xD;
             post-menopausal or surgically menopausal&#xD;
&#xD;
          -  Any ferrous or metallic materials which are contraindicated for MRI&#xD;
&#xD;
        Medication Exclusions&#xD;
&#xD;
          -  Current use of drugs with significant anticholinergic or antihistaminic properties&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hillel Grossman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai School of Medcine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samuel Gandy, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Alzheimer's Disease Research Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://icahn.mssm.edu/research/adrc/research/clinical-trials</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2014</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Hillel Grossman</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Grapeseed Extract</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Meganatural-AZ</keyword>
  <keyword>anti-oligomerization</keyword>
  <keyword>Phase 2</keyword>
  <keyword>Dietary Supplement</keyword>
  <keyword>Nutraceutical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

